Netherlands Translational Research Center B.v.

Other

Merck Sharp + Dohme Corp.

Sanofi-Aventis

Akzo Nobel N.v.

N.v. Organon

Msd Oss B.v.

Organon Biosciences Nederland B.v.

Rogier Christian Buijsman

Adrianus Petrus Antonius De Man

Guido Jenny Rudolf Zaman

Jan Gerard Sterrenburg

Joost Cornelis Marinus Uitdehaag

Joeri Johannes Petrus De Wit

Antonius Maria Van Doornmalen

Nicole Wilhelmina Cornelia Seegers

Constant Adriaan Anton Van Boeckel

Christiaan Gerardus Johannes Maria Jans

Martin De Kort

Ralf Plate

Pedro Harold Han Hermkens

Paolo Giovanni Martino Conti

Constant Van Boeckel

Dirk Gerrit Meuleman

Scott James Lusher

Johannes Egbertus Maria Basten

Adrianus Petrus De Man

Willem Hendrik Abraham Dokter

Freek Van Cauter

Cornelia Maria Tromp

Joeri Johannes De Wit

Guido Jenny Zaman

Joost Cornelis Uitdehaag

Johannes Egbertus Basten

A compound of Formula I: wherein, Rand Rindependently are selected from the group consisting of optionally substituted (6-10C)aryl and (1-5C)heteroaryl groups. The compounds can be used in pharmaceutical compositions, in particular in the treatment of cancer.

(5,6-dihydro)pyrimido[4,5-e]indolizines

(5,6-dihydro)pyrimido[4,5-E]indolizines

The invention relates to a compound of Formula (I): Formula (I), or pharmaceutically acceptable enantiomers, or salts thereof. The present invention also relates to the use of compounds of Formula (I) as selective inhibitors of indoleamine 2,3-dioxygenase. The invention also relates to the use of the compounds of Formula (I) for the treatment or prevention of diseases cancer, infections, central nervous system disease or disorder, and immune-related disorders, either as a single agent or in combination with other therapies. 

3-hydroxy-imidazolidin-4-one compounds as inhibitors of indoleamine 2,3-dioxygenase

The invention relates to a compound of Formula I: Formula I, or pharmaceutically acceptable enantiomers, or salts thereof. The present invention also relates to the use of compounds of Formula (I) as selective inhibitors of tryptophan 2,3-dioxygenase. The invention also relates to the use of the compounds of Formula (I) for the treatment or prevention of cancer and central nervous system disease or disorder, either as a single agent or in combination with other therapies. 

Inhibitors of tryptophan 2,3-dioxygenase

A compound of Formula I: or pharmaceutically acceptable enantiomers, or salts thereof. The present invention also relates to the use of compounds of Formula (I) as selective inhibitors of indoleamine 2,3-dioxygenase. The invention also relates to the use of the compounds of Formula (I) for the treatment or prevention of diseases cancer, infections, central nervous system disease or disorder, and immune-related disorders, either as a single agent or in combination with other therapies.

Inhibitors of indoleamine 2,3-dioxygenase

The present invention relates to compounds having general Formula (I) or a pharmaceutically acceptable salt thereof. The present invention also relates to pharmaceutical compositions comprising said compounds and the use of these derivatives to modulate glucocorticoid receptor activity. 

Non steroidal glucocorticoid receptor modulators

The present invention relates compounds of the formula Aoligosaccharide-spacer-GpIIb/IIIa antagonist &#x2003;&#x2003;(A). The compounds of the invention have antithrombotic activity and can be used in treating or preventing thrombotic diseases.

Antithrombotic compound

Antithrombotic compounds

Growing community of inventors

Oss, Netherlands

Rogier Christian Buijsman